Is there a role for oral blockade of platelet glycoprotein IIb/IIIa receptors in coronary and cerebrovascular disease?

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.12, Iss.10, 2003-10, pp. : 1709-1712

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Potential Role of Platelet Glycoprotein IIb/IIIa Antagonists in Cerebrovascular Disorders

By Mousa S.A.

CNS Drugs, Vol. 13, Iss. 3, 2000-03 ,pp. : 155-160

Adis International

Access to resources Recommend Favorite

Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker

By Liu F. Craft R.M. Morris S.A. Carroll R.C.

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 11, 2000-11 ,pp. : 2673-2687

Informa Healthcare

Access to resources Recommend Favorite

The Use of Roxifiban (DMP754), a Novel Oral Platelet Glycoprotein IIb/IIIa Receptor Inhibitor, in Patients with Stable Coronary Artery Disease

By Murphy J.

American Journal of Cardiovascular Drugs, Vol. 3, Iss. 2, 2003-01 ,pp. : 101-112

Adis International

Access to resources Recommend Favorite

Platelet Glycoprotein IIb/IIIa Polymorphism and Coronary Artery Disease: Implications for Clinical Practice

By Augusto Di Castelnuovo Giovanni de Gaetano Maria Benedetta Donati Iacoviello Licia

American Journal of PharmacoGenomics, Vol. 5, Iss. 2, 2005-01 ,pp. : 93-99

Adis International

Access to resources Recommend Favorite

Platelet glycoprotein IIb/IIIa antagonists in clinical trials for the treatment of coronary artery disease

By Salam Amar M Al Suwaidi Jassim

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 11, 2002-11 ,pp. : 1645-1658

Informa Healthcare

Access to resources Recommend Favorite